The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Related Articles
MD-Granting Medical Schools in the US, 2023-2024
This Appendix presents data derived from the 2023-2024 Liaison Committee on Medical Education Annual Medical School Questionnaire-Part II.
FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.
Measurable residual disease monitoring in AML: Prospects for therapeutic decisionâmaking and new drug development
Measurable residual disease (MRD) is strongly associated with risk of relapse and long-term survival outcomes in patients with acute myeloid leukemia (AML). Apart from its…
When to Stay or Leave Your Physician Job – FREE Webinar
At the free, LIVE class, you’ll get everything you need to make your decision & upgrade your job in 2025, regardless if you stay or…
Pain perception while listening to thrash heavy metal vs relaxing music at a heavy metal festival â the CoPainHell study â a factorial randomized non-blinded crossover trial
Objectives Music festivals are often a source of joy, but also a risk of injury. While previous studies suggest music can relieve pain, its effect…
Physician (Radiation Oncologist) – Recruitment/Relocation Incentive-EDRP Authorized
This position is eligible for the Education Debt Reduction Program (EDRP), a student loan payment reimbursement program. You must meet specific individual eligibility requirements in…
Tislelizumab Scores FDA Approval in Advanced Gastric and GEJ Cancers
The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.
Targeting the ubiquitin proteasome system in cancer stem cells
Over the past few years there has been an alarming burst of cancer burden worldwide. Cancer stem cells (CSCs) act as hidden devils within tumors,…
Sotorasib in KRAS p.G12CâMutated Advanced Pancreatic Cancer | NEJM
KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated…
Pancreatic cancer
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common…